We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Pioglitazone in Hypertensive Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01472497
First Posted: November 16, 2011
Last Update Posted: June 5, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Kazuhide Ogino, Tottori University Hospital
  Purpose
Insulin resistance is often complicated with hypertension. AGE and inflammation play important roles in insulin resistance. Some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. The aim of this study to evaluate the effect of pioglitazone compared with glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive patients during oral glucose tolerance test.

Condition Intervention Phase
Hypertension Insulin Resistance Drug: Pioglitazone Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -

Resource links provided by NLM:


Further study details as provided by Kazuhide Ogino, Tottori University Hospital:

Primary Outcome Measures:
  • advanced glycation end-product (AGE) [ Time Frame: 24 weeks ]
  • inflammatory cytokines (TNF-alfa, IL-6 and MCP-1) [ Time Frame: 24 weeks ]
  • cardiac function (echo and BNP) [ Time Frame: 24 weeks ]

Enrollment: 16
Study Start Date: April 2007
Study Completion Date: March 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: glymepiride Drug: Pioglitazone
pioglitazone (15mg) once a day for 24 weeks
Other Name: actos

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hypertension with insulin resistance

Exclusion Criteria:

  • Chronic systolic heart failure, ACS
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01472497


Locations
Japan
Tottori University Hospital
Yonago, Japan, 683-8504
Sponsors and Collaborators
Tottori University Hospital
Investigators
Principal Investigator: Kazuhide Ogino, MD Tottori University Hospital
  More Information

Responsible Party: Kazuhide Ogino, Associate Professor, Tottori University Hospital
ClinicalTrials.gov Identifier: NCT01472497     History of Changes
Other Study ID Numbers: PIO and HTN
First Submitted: July 21, 2011
First Posted: November 16, 2011
Last Update Posted: June 5, 2012
Last Verified: June 2012

Keywords provided by Kazuhide Ogino, Tottori University Hospital:
hypertension
insulin resistance
oral glucose tolerance test
AGE
inflammatory cytokine

Additional relevant MeSH terms:
Hypertension
Insulin Resistance
Vascular Diseases
Cardiovascular Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Pioglitazone
Hypoglycemic Agents
Physiological Effects of Drugs